Quarterly Report • Nov 8, 2022
Quarterly Report
Open in ViewerOpens in native device viewer
3rd quarter | First nine months 2022
| 3rd quarter | 1st nine months | |||
|---|---|---|---|---|
| in € million | 2021 | 2022 | 2021 | 2022 |
| Sales | 3,871 | 4,878 | 10,865 | 14,148 |
| Adjusted EBITDAa | 645 | 615 | 1,881 | 2,077 |
| Adjusted EBITDA margin in % | 16.7 | 12.6 | 17.3 | 14.7 |
| Adjusted EBITb | 387 | 342 | 1,121 | 1,270 |
| Income before financial result and income taxes, continuing operations (EBIT) | 373 | 326 | 1,060 | 1,202 |
| Net income | 235 | 214 | 640 | 824 |
| Adjusted net income | 269 | 253 | 762 | 960 |
| Earnings per share in € | 0.50 | 0.46 | 1.37 | 1.77 |
| Adjusted earnings per share in € | 0.58 | 0.54 | 1.63 | 2.06 |
| Cash flow from operating activities, continuing operations | 701 | 517 | 1,467 | 752 |
| Cash outflows for investments in intangible assets, property, plant and equipment | -177 | -229 | -530 | -570 |
| Free cash flowc | 524 | 288 | 937 | 182 |
| Net financial debt as of September 30 | – | – | -2,741 | -3,807 |
| No. of employees as of September 30 | – | – | 32,891 | 33,836 |
a Earnings before financial result, taxes, depreciation, and amortization, after adjustments, continuing operations.
b Earnings before financial result and taxes, after adjustments, continuing operations.
c Cash flow from operating activities, continuing operations, less cash outflows for investments in intangible assets, property, plant and equipment.
Due to rounding, some figures in this report may not add up exactly to the totals stated.
| 2 |
|---|
| 2 |
| 6 |
| 12 |
| 14 |
| 17 |
| 18 |
| 19 |
| 20 |
| 24 |
| 25 |
| 25 |
Given the challenging conditions, Evonik performed satisfactorily overall. The supply situation for raw materials, packaging, and logistics eased slightly, although conditions remained challenging, especially as a consequence of the war in Ukraine. The sharp hike in raw material and energy prices and general inflationary pressure had a considerable impact on supply chains, with bottlenecks in the supply of some materials that are dependent on natural gas.
Despite these difficulties, our business development was solid. Although volumes declined, the substantial rise in variable costs was more than offset by raising selling prices. Overall, adjusted EBITDA was only slightly lower than in the prior-year period.
The Evonik Group's sales increased by 26 percent to €4,878 million. Organic sales growth was 10 percent as a result of a significant improvement in selling prices, while volumes were lower. Moreover, positive currency effects and other effects contributed to the sales growth. The other effects resulted, in particular, from trading in gas and electricity by the Technology & Infrastructure division to supply external customers.
| in % | 1st quarter 2022 | 2nd quarter 2022 | 3rd quarter 2022 | 1st nine months 2022 |
|---|---|---|---|---|
| Volumes | 4 | -2 | -7 | -2 |
| Prices | 22 | 24 | 17 | 21 |
| Organic sales growth | 26 | 22 | 10 | 19 |
| Exchange rates | 4 | 5 | 7 | 5 |
| Change in the scope of consolidation/other effects | 4 | 4 | 9 | 6 |
| Total | 34 | 31 | 26 | 30 |
Adjusted EBITDA decreased by 5 percent to €615 million. Earnings were lower in Nutrition & Care and Performance Materials, Smart Materials held earnings at the prior-year level, and Specialty Additives posted a considerable rise in earnings. The adjusted EBITDA margin fell from 16.7 percent in the third quarter of 2021 to 12.6 percent.
| 3rd quarter | 1st nine months | ||||||
|---|---|---|---|---|---|---|---|
| in € million | 2021 | 2022 | Change in % | 2021 | 2022 | Change in % | |
| Sales | 3,871 | 4,878 | 26 | 10,865 | 14,148 | 30 | |
| Adjusted EBITDA | 645 | 615 | -5 | 1,881 | 2,077 | 10 | |
| Adjusted depreciation, amortization, and impairment | |||||||
| losses | -258 | -273 | -760 | -807 | |||
| Adjusted EBIT | 387 | 342 | -12 | 1,121 | 1,270 | 13 | |
| Adjustments | -14 | -16 | -61 | -68 | |||
| thereof restructuring | -5 | -3 | -18 | -26 | |||
| thereof impairment losses/reversal of impairment losses |
– | – | – | – | |||
| thereof acquisition/divestment of shareholdings | -5 | -3 | -11 | -8 | |||
| thereof other | -4 | -10 | -32 | -34 | |||
| Income before financial result and income taxes, | |||||||
| continuing operations (EBIT) | 373 | 326 | -13 | 1,060 | 1,202 | 13 | |
| Financial result | -37 | -21 | -98 | -28 | |||
| Income before income taxes, continuing | |||||||
| operations | 336 | 305 | -9 | 962 | 1,174 | 22 | |
| Income taxes | -100 | -90 | -300 | -339 | |||
| Income after taxes, continuing operations | 236 | 215 | -9 | 662 | 835 | 26 | |
| Income after taxes, discontinued operations | 4 | – | -6 | – | |||
| Income after taxes | 240 | 215 | -10 | 656 | 835 | 27 | |
| thereof income attributable to non-controlling | |||||||
| interests | 5 | 1 | 16 | 11 | |||
| Net income | 235 | 214 | -9 | 640 | 824 | 29 | |
| Earnings per share in € | 0.50 | 0.46 | 1.37 | 1.77 |
The adjustments of -€16 million contained restructuring expenses in connection with the divestment of a business in the Performance Materials division. Further expenses included, among other things, the integration of acquisitions made in the past. The financial result improved to -€21 million, thanks to lower interest expense and, above all, higher interest income as a result of the higher discount rate applied to other provisions. Overall, income before income taxes, continuing operations was 9 percent lower at €305 million. Net income declined by 9 percent to €214 million.
Adjusted net income fell 6 percent to €253 million. Adjusted earnings per share dropped from €0.58 to €0.54.
| 3rd quarter | 1st nine months | ||||||
|---|---|---|---|---|---|---|---|
| in € million | 2021 | 2022 | Change in % | 2021 | 2022 | Change in % | |
| Adjusted EBITDA | 645 | 615 | -5 | 1,881 | 2,077 | 10 | |
| Adjusted depreciation, amortization, and | |||||||
| impairment losses | -258 | -273 | -760 | -807 | |||
| Adjusted EBIT | 387 | 342 | -12 | 1,121 | 1,270 | 13 | |
| Adjusted financial result | -37 | -21 | -108 | -28 | |||
| Amortization and impairment losses on | |||||||
| intangible assets | 37 | 39 | 108 | 122 | |||
| Adjusted income before income taxesa | 387 | 360 | -7 | 1,121 | 1,364 | 22 | |
| Adjusted income taxes | -113 | -106 | -343 | -393 | |||
| Adjusted income after taxesa | 274 | 254 | -7 | 778 | 971 | 25 | |
| thereof adjusted income attributable to | |||||||
| non-controlling interests | 5 | 1 | 16 | 11 | |||
| Adjusted net incomea | 269 | 253 | -6 | 762 | 960 | 26 | |
| Adjusted earnings per share in €a | 0.58 | 0.54 | 1.63 | 2.06 |
a Continuing operations.
Sales grew by 30 percent to €14,148 million thanks to higher selling prices, mainly to pass on the significant increase in variable costs. Adjusted EBITDA improved 10 percent to €2,077 million. The adjusted EBITDA margin dropped to 14.7 percent, compared with 17.3 percent in the first nine months of 2021.
The adjustments of -€68 million included restructuring expenses of €26 million, principally for a new group-wide project to optimize administrative functions and the sale of a business in the Performance Materials division. Expenses for the acquisition of shareholdings related to the integration of acquisitions made in the past. The line item "Other" contains, among other things, expenses for the recognition of power derivatives, the reorganization of the superabsorbents business, and the termination of a project in Russia. In the prior-year period, the adjustments mainly comprised restructuring expenses, principally for a site in the Nutrition & Care division, and expenses in connection with the settlement of a legal dispute. The financial result improved substantially to -€28 million, thanks to lower interest expense and, above all, higher interest income as a result of the higher discount rate applied to other provisions. In addition, the reduction in the interest rate applied to interest on taxes had a positive effect. The prior-year figure contained special items of €10 million for interest income in connection with a claim to a value-added tax refund. The adjusted financial result improved from -€108 million to -€28 million. Income before income taxes, continuing operations was 22 percent higher at €1,174 million. Net income rose 29 percent to €824 million.
Adjusted net income improved by 26 percent to €960 million, while adjusted earnings per share increased from €1.63 to €2.06.
| 3rd quarter | 1st nine months | ||||||
|---|---|---|---|---|---|---|---|
| in € million | 2021 | 2022 | Change in % | 2021 | 2022 | Change in % | |
| External sales | 934 | 1,113 | 19 | 2,763 | 3,278 | 19 | |
| Adjusted EBITDA | 224 | 243 | 8 | 739 | 758 | 3 | |
| Adjusted EBITDA margin in % | 24.0 | 21.8 | – | 26.7 | 23.1 | – | |
| Adjusted EBIT | 181 | 194 | 7 | 609 | 613 | 1 | |
| Capital expendituresa | 20 | 28 | 40 | 50 | 68 | 36 | |
| No. of employees as of September 30 | – | – | – | 3,704 | 3,785 | 2 |
a Capital expenditures for intangible assets, property, plant and equipment.
In the Specialty Additives division, sales rose 19 percent to €1,113 million in the third quarter of 2022. The sales growth resulted from considerably higher selling prices, as higher variable costs were passed on to customers, and positive currency effects. By contrast, volumes declined.
Products for the construction and coating industries and for renewable energies generated considerably higher sales as a result of successful price rises to offset higher costs. Sales of additives for polyurethane foams and consumer durables also increased, primarily on price grounds. Sales of additives for the automotive sector rose due to slightly higher volumes and improved prices.
Adjusted EBITDA rose 8 percent to €243 million, driven by price adjustments, which more than offset the rise in raw material, energy, and logistics costs, and by positive currency effects. The adjusted EBITDA margin dropped back from a high level of 24.0 percent in the prior-year period to 21.8 percent.
In the first nine months of 2022, sales in the Specialty Additives division increased by 19 percent to €3,278 million. Since volumes were slightly lower, this was attributable to a significant rise in selling prices, mainly to pass on higher variable costs, and positive currency effects. Adjusted EBITDA improved 3 percent to €758 million. The adjusted EBITDA margin was 23.1 percent, which was below the high prior-year margin of 26.7 percent.
| 3rd quarter | 1st nine months | ||||||
|---|---|---|---|---|---|---|---|
| in € million | 2021 | 2022 | Change in % | 2021 | 2022 | Change in % | |
| External sales | 931 | 1,062 | 14 | 2,549 | 3,127 | 23 | |
| Adjusted EBITDA | 192 | 148 | -23 | 517 | 555 | 7 | |
| Adjusted EBITDA margin in % | 20.6 | 13.9 | – | 20.3 | 17.7 | – | |
| Adjusted EBIT | 127 | 82 | -35 | 327 | 357 | 9 | |
| Capital expendituresa | 30 | 64 | 113 | 85 | 130 | 53 | |
| No. of employees as of September 30 | – | – | – | 5,386 | 5,680 | 5 |
a Capital expenditures for intangible assets, property, plant and equipment.
In the Nutrition & Care division, sales rose 14 percent to €1,062 million in the third quarter of 2022. The reasons for this were significantly higher selling prices and positive currency effects. By contrast, volumes declined, mainly because of lower demand from the animal feed industry.
Despite lower volumes, essential amino acids posted significant sales growth as a result of improved selling prices. Sales of health and care products increased, thanks to a continuing positive trend in active ingredients for cosmetic applications.
Adjusted EBITDA decreased by 23 percent to €148 million due to lower volumes and higher raw material costs. The adjusted EBITDA margin fell from 20.6 percent in the prior-year period to 13.9 percent.
In the first nine months of 2022, the Nutrition & Care division's sales grew 23 percent to €3,127 million. This was principally due to the improvement in selling prices and positive currency effects. Adjusted EBITDA rose 7 percent to €555 million, mainly because of the positive price trend. The adjusted EBITDA margin declined from 20.3 percent in the prior-year period to 17.7 percent.
| 3rd quarter | 1st nine months | ||||||
|---|---|---|---|---|---|---|---|
| in € million | 2021 | 2022 | Change in % | 2021 | 2022 | Change in % | |
| External sales | 1,002 | 1,259 | 26 | 2,885 | 3,677 | 27 | |
| Adjusted EBITDA | 177 | 177 | – | 527 | 572 | 9 | |
| Adjusted EBITDA margin in % | 17.7 | 14.1 | – | 18.3 | 15.6 | – | |
| Adjusted EBIT | 111 | 103 | -7 | 329 | 355 | 8 | |
| Capital expendituresa | 78 | 69 | -12 | 224 | 174 | -22 | |
| No. of employees as of September 30 | – | – | – | 7,731 | 7,919 | 2 |
a Capital expenditures for intangible assets, property, plant and equipment.
In the Smart Materials division, sales grew 26 percent to €1,259 million in the third quarter of 2022. While volumes were basically stable, this resulted from a significant increase in selling prices and positive currency effects.
There was a substantial rise in sales of inorganic products. Demand was stable overall, and it was possible to raise selling prices significantly to recoup the rise in variable costs. Although volumes were almost unchanged, the Polymers business also registered considerably higher sales than in the prior-year period, thanks to improved selling prices.
Adjusted EBITDA was €177 million, in line with the prior-year level. The adjusted EBITDA margin fell from 17.7 percent in the prior-year period to 14.1 percent.
In the first nine months of 2022, sales in the Smart Materials division increased by 27 percent to €3,677 million, driven by volumes and prices. Adjusted EBITDA improved 9 percent to €572 million. The adjusted EBITDA margin dropped from 18.3 percent in the prior-year period to 15.6 percent.
| 3rd quarter | 1st nine months | ||||||
|---|---|---|---|---|---|---|---|
| in € million | 2021 | 2022 | Change in % | 2021 | 2022 | Change in % | |
| External sales | 784 | 903 | 15 | 2,071 | 2,893 | 40 | |
| Adjusted EBITDA | 97 | 74 | -24 | 237 | 334 | 41 | |
| Adjusted EBITDA margin in % | 12.4 | 8.2 | – | 11.4 | 11.5 | – | |
| Adjusted EBIT | 63 | 39 | -38 | 138 | 234 | 70 | |
| Capital expendituresa | 14 | 16 | 14 | 32 | 39 | 22 | |
| No. of employees as of September 30 | – | – | – | 1,962 | 2,031 | 4 |
a Capital expenditures for intangible assets, property, plant and equipment.
Sales in the Performance Materials division climbed 15 percent to €903 million in the third quarter of 2022, with contributions coming from considerably higher prices and positive currency effects, whereas volumes decreased.
The C4 business reported lower demand, but sales were up slightly as a result of the improvement in selling prices. Sales of superabsorbents rose significantly due to higher selling prices, mainly to recoup the increase in raw material costs.
Adjusted EBITDA fell 24 percent to €74 million as a consequence of lower product margins. The adjusted EBITDA margin decreased to 8.2 percent, down from 12.4 percent in the prior-year period.
In the first nine months of 2022, sales in the Performance Materials division grew 40 percent to €2,893 million, with volumes down slightly while prices were significantly higher. Adjusted EBITDA increased by 41 percent to €334 million, mainly due to the considerable improvement in margins in the two previous quarters. The adjusted EBITDA margin was 11.5 percent, which was around the prior-period level (11.4 percent).
| 3rd quarter | 1st nine months | ||||||
|---|---|---|---|---|---|---|---|
| in € million | 2021 | 2022 | Change in % | 2021 | 2022 | Change in % | |
| External sales | 204 | 525 | 157 | 553 | 1,124 | 103 | |
| Adjusted EBITDA | 27 | 35 | 30 | 82 | 65 | -21 | |
| Adjusted EBITDA margin in % | 13.2 | 6.7 | – | 14.8 | 5.8 | – | |
| Adjusted EBIT | -1 | 6 | – | -1 | -21 | – | |
| Capital expendituresa | 34 | 31 | -9 | 84 | 71 | -15 | |
| No. of employees as of September 30 | – | – | – | 8,154 | 8,308 | 2 |
a Capital expenditures for intangible assets, property, plant and equipment.
In the Technology & Infrastructure division, sales were 157 percent higher at €525 million in the third quarter of 2022, driven principally by higher natural gas and electricity prices in energy trading with external customers at our sites. Adjusted EBITDA increased by 30 percent to €35 million as a result of cost optimization. The adjusted EBITDA margin decreased from 13.2 percent to 6.7 percent.
In the first nine months of 2022, sales were up 103 percent at €1,124 million. Adjusted EBITDA declined by 21 percent to €65 million, mainly as a consequence of the increased cost of supplying energy. The adjusted EBITDA margin fell from 14.8 percent to 5.8 percent.
The cash flow from operating activities, continuing operations decreased by €715 million to €752 million in the first nine months of 2022. This resulted, above all, from a significant increase in net working capital as a consequence of the rise in raw material prices and higher cash outflows for bonus payments. The free cash flow was therefore €755 million below the prior-year period at €182 million.
| 1st nine months | ||
|---|---|---|
| in € million | 2021 | 2022 |
| Cash flow from operating activities, continuing operations | 1,467 | 752 |
| Cash outflows for investments in intangible assets, property, plant and equipment | -530 | -570 |
| Free cash flow | 937 | 182 |
| Cash flow from other investing activities, continuing operations | 4 | 121 |
| Cash flow from financing activities, continuing operations | -688 | 322 |
| Change in cash and cash equivalents | 253 | 625 |
The cash flow from other investing activities was €121 million and contained proceeds from the sale of current securities. The cash inflow from financing activities was €322 million and mainly related to the issuance of a new bond (€750 million) and new Schuldschein loans (€250 million), while payment of the dividend for fiscal 2021 resulted in a cash outflow of €545 million.
Net financial debt was €3,807 million, an increase of €950 million compared with December 31, 2021. This was principally due to the payment of the dividend for the previous fiscal year and additions of lease liabilities, especially due to the start-up of a gas and steam power plant in Marl (Germany).
| in € million | Dec. 31, 2021 | Sep. 30, 2022 |
|---|---|---|
| Non-current financial liabilitiesa | -3,527 | -4,001 |
| Current financial liabilitiesa | -232 | -1,180 |
| Financial debt | -3,759 | -5,181 |
| Cash and cash equivalents | 456 | 1,078 |
| Current securities | 446 | 296 |
| Financial assets | 902 | 1,374 |
| Net financial debt | -2,857 | -3,807 |
a Excluding derivatives and excluding the liabilities under rebate and bonus agreements.
The bond due in January 2023, which had a nominal value of €750 million, was reclassified from non-current to current financial liabilities. Evonik fully redeemed this bond in October 2022 by exercising a repayment right contained in the bond terms. To refinance this bond, in May 2022, Evonik Industries AG issued a green bond with a nominal value of €750 million and a tenor of 5 years and 4 months. The issue price was 99.386 percent, and the annual coupon is 2.25 percent. The proceeds from the issue will be used primarily to fund investment in our Next Generation Solutions1. To further strengthen liquidity, in August 2022, we issued Schuldschein loans with a nominal value of €250 million and a tenor of three, four, and seven years in several fixed and variable interest tranches.
In the first nine months of 2022, capital expenditures for property, plant and equipment amounted to €519 million (9M 2021: €505 million). In principle, there is a slight timing difference in cash outflows for property, plant and equipment. The expansion of capacity for isobutene derivatives at the C4 production complex in Marl (Germany) was completed. In June 2022, the groundbreaking ceremony was held for the production plant for bio-based rhamnolipids, which is currently being constructed in Slovenská L'upca (Slovakia). Investment in this plant is in the triple-digit million euro range.
1 Next Generation Solutions are products and solutions which our analysis shows have a strong sustainability profile that is above, or even well above, the market reference level.
Our expectations for the global economic situation in 2022 have deteriorated further since the beginning of the year and are still dominated by a high degree of uncertainty. Overall, compared with 2021, we now assume lower global economic growth of 2.6 percent year-on-year in 2022 (growth assumption at the start of the year: 4.2 percent).2
The development of the global economy depends, in particular, on the further course of the war in Ukraine and its knockon effects. Persistently high or rising raw material, energy, and food prices could result in inflation becoming established at a high level, reducing disposable income and thus consumer spending.
Moreover, supply bottlenecks or a gas shortage would represent a substantial risk for the European chemical industry and the entire economy. The emergence of new coronavirus mutations and China's zero-Covid policy could lead to further disruption of global supply chains and renewed economic downturns. That would also adversely affect demand in Evonik's end-customer industries. In addition, the significant tightening of monetary policy has increased the risk of recession and a financial crisis. Last but not least, the development of the global economy could be below our expectations as a result of other geopolitical conflicts.
In view of the developments outlined above, we predict that the price of Evonik-specific raw materials will be significantly higher in 2022 than in 2021.
Our forecast is based on the following assumptions:
Despite the difficult global economic situation, Evonik achieved a successful operating performance in the first nine months of this year. The three growth divisions are benefiting from structural trends and continuing their positive long-term development. Equally positively, we are seeing increased demand from customers for our Next Generation Solutions, in other words, Evonik products and solutions with a superior sustainability profile. Moreover, we expect our six innovation growth fields3 to make a further contribution to growth in 2022. Our successful increases in selling prices offset the significant rise in raw material, energy, and logistics costs in the first nine months. Consequently, Evonik now anticipates that full-year sales will be around €18.5 billion (previously: between €17.0 billion and €18.0 billion; 2021: €15.0 billion). Our expectation for adjusted EBITDA is unchanged at between €2.5 billion and €2.6 billion (2021: €2,383 million). This is based on the assumption that the macroeconomic slowdown that started in the third quarter will continue and that the supply of gas will be sufficient to maintain production on the necessary scale. To be optimally prepared for a potential shortage of gas, Evonik is implementing extensive measures at its German sites to enable it to switch from natural gas to alternative energy sources.
2 Based on data from IHS Markit as of September 12, 2022.
3 See section 4. Research and development in the 2021 financial report.
We expect the development of the chemicals divisions to be as follows:
We still expect the Specialty Additives division to develop positively in 2022, driven by customer-specific solutions for more sustainable products with improved properties. Our own price rises have now offset the increases in raw material, energy, and logistics costs. Moreover, in the remainder of the year, restrictions on the availability of individual raw materials should decline further. Overall, we still anticipate that this division's earnings will be slightly above the prior-year level (2021: €920 million).
As in previous years, the Nutrition & Care division is benefiting from the continuing structural growth trend in its resilient end-markets. This division's growth will increasingly be determined by its clear focus on system solutions in the consumer goods, nutrition, and health care businesses. Following a strong first half, business development has weakened in the second half of the year. Therefore, we now expect this division's earnings to be around the prior-year level (previously: considerably higher than in the prior year; 2021: €717 million).
We still assume positive growth momentum in the Smart Materials division. This trend is driven primarily by the Inorganics business, which is benefiting from good demand for silicas and silanes for a wide range of applications as well as for catalysts. Higher raw material costs are being offset by our own price rises. In all, we expect earnings to be considerably higher than in the prior year (2021: €650 million).
In the Performance Materials division, we should benefit from a market improvement in the superabsorbents business and our long-standing customer relationships. Following the clearly positive impact of the higher naphtha price and better product margins on the performance of our C4 derivatives, especially in the first half of the year, we expect this division's earnings to be significantly higher than in the prior year (2021: €317 million).
For Technology & Infrastructure and Others4 , we assume that overall earnings will be considerably less negative than in the previous year (2021: -€221 million) despite the increase in energy costs and personnel expenses. 2021 was impacted, among other things, by insurance deductibles for weather-related damage in Europe and the USA and by power plant outages in Germany.
In 2022, the return on capital employed (ROCE) is expected to be slightly above the previous year's level (2021: 9.0 percent).
We still expect cash outflows for investments in intangible assets, property, plant and equipment to be around €900 million in 2022 (2021: €865 million).
So far this year, the free cash flow has been affected by higher cash outflows from net working capital (mainly due to higher raw material costs and measures to prevent supply bottlenecks). We are continuing our efforts to reduce net working capital this year. Nevertheless, we anticipate a significant cash outflow for the full year. Moreover, as expected, the free cash flow was held back by higher bonuses for 2021. Our consistently high investment discipline has a stabilizing effect. Following the change of momentum and a clearly positive free cash flow in the third quarter, we now expect cash flow generation to gain even more strength in the fourth quarter. Consequently, for the free cash flow 2022, we assume a cash conversion rate5 of around 30 percent (2021: 40 percent). With adjusted EBITDA expected to be between €2.5 billion and €2.6 billion, the absolute free cash flow is therefore likely to be below the prior-year level (2021: €950 million).
4 Enabling functions, other activities, consolidation.
5 Ratio of free cash flow to adjusted EBITDA.
| Forecast performance indicators | 2021 | Forecast for 2022a | Revised forecast as of August 2022b |
Current forecast for 2022 |
|---|---|---|---|---|
| Group sales | €15.0 billion | Between €15.5 billion and €16.5 billion |
Between €17.0 billion and €18.0 billion |
Around €18.5 billion |
| Adjusted EBITDA | €2.4 billion | Between €2.5 billion and €2.6 billion |
Between €2.5 billion and €2.6 billion |
Between €2.5 billion and €2.6 billion |
| ROCE | 9.0% | Slightly above the prior-year level |
Slightly above the prior-year level |
Slightly above the prior-year level |
| Cash outflows for investments in intangible assets, property, plant and equipment |
€865 million | Around €900 million | Around €900 million | Around €900 million |
| Free cash flow: cash conversion ratec | 40% | Around 40% | Around 30% | Around 30% |
a As in the financial report 2021.
b As in the half-year financial report 2022.
c Ratio of free cash flow to adjusted EBITDA.
| 3rd quarter | 1st nine months | ||||
|---|---|---|---|---|---|
| in € million | 2021 | 2022 | 2021 | 2022 | |
| Sales | 3,871 | 4,878 | 10,865 | 14,148 | |
| Cost of sales | -2,807 | -3,784 | -7,741 | -10,619 | |
| Gross profit on sales | 1,064 | 1,094 | 3,124 | 3,529 | |
| Selling expenses | -436 | -540 | -1,244 | -1,544 | |
| Research and development expenses | -118 | -115 | -333 | -340 | |
| General administrative expenses | -148 | -129 | -406 | -414 | |
| Other operating income | 43 | 71 | 143 | 175 | |
| Other operating expense | -34 | -56 | -230 | -212 | |
| Result from investments recognized at equity | 2 | 1 | 6 | 8 | |
| Income before financial result and income taxes, continuing operations (EBIT) | 373 | 326 | 1,060 | 1,202 | |
| Interest income | 5 | 24 | 25 | 75 | |
| Interest expense | -34 | -32 | -101 | -80 | |
| Other financial income/expense | -8 | -13 | -22 | -23 | |
| Financial result | -37 | -21 | -98 | -28 | |
| Income before income taxes, continuing operations | 336 | 305 | 962 | 1,174 | |
| Income taxes | -100 | -90 | -300 | -339 | |
| Income after taxes, continuing operations | 236 | 215 | 662 | 835 | |
| Income after taxes, discontinued operations | 4 | – | -6 | – | |
| Income after taxes | 240 | 215 | 656 | 835 | |
| thereof attributable to non-controlling interests | 5 | 1 | 16 | 11 | |
| thereof attributable to shareholders of Evonik Industries AG (net income) | 235 | 214 | 640 | 824 | |
| Earnings per share in € (basic and diluted) | 0.50 | 0.46 | 1.37 | 1.77 | |
| thereof continuing operations | 0.49 | 0.46 | 1.38 | 1.77 | |
| thereof discontinued operations | 0.01 | 0.00 | -0.01 | 0.00 |
Prior-year figures restated.
| in € million | Dec. 31, 2021 | Sep. 30, 2022 |
|---|---|---|
| Goodwill | 4,785 | 5,095 |
| Other intangible assets | 1,260 | 1,237 |
| Property, plant and equipment | 6,963 | 7,239 |
| Right-of-use assets | 608 | 896 |
| Investments recognized at equity | 81 | 83 |
| Other financial assets | 581 | 403 |
| Deferred taxes | 1,755 | 1,091 |
| Other income tax assets | 16 | 18 |
| Other non-financial assets | 125 | 79 |
| Non-current assets | 16,174 | 16,141 |
| Inventories | 2,548 | 3,450 |
| Trade accounts receivable | 1,954 | 2,327 |
| Other financial assets | 571 | 441 |
| Other income tax assets | 199 | 151 |
| Other non-financial assets | 382 | 595 |
| Cash and cash equivalents | 456 | 1,078 |
| 6,110 | 8,042 | |
| Assets held for sale | – | 98 |
| Current assets | 6,110 | 8,140 |
| Total assets | 22,284 | 24,281 |
| Issued capital | 466 | 466 |
| Capital reserve | 1,168 | 1,168 |
| Retained earnings | 7,767 | 9,596 |
| Other equity components | -112 | 483 |
| Equity attributable to shareholders of Evonik Industries AG | 9,289 | 11,713 |
| Non-controlling interests | 83 | 84 |
| Equity | 9,372 | 11,797 |
| Provisions for pensions and other post-employment benefits | 3,766 | 1,655 |
| Other provisions | 657 | 628 |
| Other financial liabilities | 3,531 | 4,043 |
| Deferred taxes | 628 | 678 |
| Other income tax liabilities | 195 | 209 |
| Other non-financial liabilities | 143 | 164 |
| Non-current liabilities | 8,920 | 7,377 |
| Other provisions | 892 | 739 |
| Trade accounts payable | 2,022 | 2,013 |
| Other financial liabilities | 477 | 1,521 |
| Other income tax liabilities | 211 | 225 |
| Other non-financial liabilities | 390 | 596 |
| 3,992 | 5,094 | |
| Liabilities associated with assets held for sale | – | 13 |
| Current liabilities | 3,992 | 5,107 |
| Total equity and liabilities | 22,284 | 24,281 |
| 3rd quarter | 1st nine months | |||
|---|---|---|---|---|
| in € million | 2021 | 2022 | 2021 | 2022 |
| Income before financial result and income taxes, continuing operations | 373 | 326 | 1,060 | 1,202 |
| Depreciation, amortization, impairment losses/reversal of impairment losses on | ||||
| non-current assets | 260 | 275 | 761 | 813 |
| Result from investments recognized at equity | -2 | -2 | -6 | -8 |
| Gains/losses on the disposal of non-current assets | – | – | 21 | 3 |
| Change in inventories | -181 | -123 | -500 | -737 |
| Change in trade accounts receivable | -62 | 192 | -382 | -270 |
| Change in trade accounts payable | 84 | -184 | 324 | -19 |
| Change in provisions for pensions and other post-employment benefits | 10 | -5 | 52 | 25 |
| Change in other provisions | 163 | 85 | 107 | -138 |
| Change in miscellaneous assets/liabilities | 40 | 12 | 90 | 54 |
| Cash inflows from dividends | 1 | – | 18 | 15 |
| Cash outflows for income taxes | -57 | -78 | -194 | -288 |
| Cash inflows from income taxes | 72 | 19 | 116 | 100 |
| Cash flow from operating activities, continuing operations | 701 | 517 | 1,467 | 752 |
| Cash outflows for investments in intangible assets, property, plant and equipment | -177 | -229 | -530 | -570 |
| Cash outflows to obtain control of businesses | -37 | – | -39 | – |
| Cash outflows relating to the loss of control over businesses | – | – | -145 | – |
| Cash outflows for investments in other shareholdings | -6 | -6 | -10 | -18 |
| Cash inflows from divestments of intangible assets, property, plant and equipment | – | – | 8 | 3 |
| Cash inflows relating to the loss of control over businesses | – | 4 | – | 4 |
| Cash inflows from divestment of other shareholdings | 1 | – | 2 | – |
| Cash inflows/outflows relating to securities, deposits, and loans | -99 | 38 | 178 | 120 |
| Cash inflows from interest | 3 | 5 | 10 | 12 |
| Cash flow from investing activities, continuing operations | -315 | -188 | -526 | -449 |
| Cash outflows for dividends to shareholders of Evonik Industries AG | – | – | -536 | -545 |
| Cash outflows for dividends to non-controlling interests | – | -1 | -20 | -11 |
| Cash outflows due to changes in ownership interests in subsidiaries | – | -5 | – | -5 |
| Cash outflows for the purchase of treasury shares | – | – | -15 | -16 |
| Cash inflows from the sale of treasury shares | – | – | 12 | 12 |
| Cash inflows from the addition of financial liabilities | 533 | 426 | 617 | 1,508 |
| Cash outflows for repayment of financial liabilities | -573 | -331 | -758 | -472 |
| Cash inflows/outflows in connection with financial transactions | -5 | -39 | 84 | -103 |
| Cash outflows for interest | -38 | -23 | -72 | -46 |
| Cash flow from financing activities, continuing operations | -83 | 27 | -688 | 322 |
| Change in cash and cash equivalents | 303 | 356 | 253 | 625 |
| Cash and cash equivalents as of July 1/January 1 | 520 | 731 | 563 | 456 |
| Change in cash and cash equivalents | 303 | 356 | 253 | 625 |
| Changes in exchange rates and other changes in cash and cash equivalents | -2 | 4 | 5 | 10 |
| Cash and cash equivalents as of September 30 | 821 | 1,091 | 821 | 1,091 |
| Cash and cash equivalents included in assets held for sale | – | 13 | – | 13 |
| Cash and cash equivalents as on the balance sheet as of September 30 | 821 | 1,078 | 821 | 1,078 |
| Specialty Additives | Nutrition & Care | Smart Materials | ||||
|---|---|---|---|---|---|---|
| in € million | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 |
| External sales | 934 | 1,113 | 931 | 1,062 | 1,002 | 1,259 |
| Internal sales | 2 | 2 | -1 | 3 | 21 | 26 |
| Total sales | 936 | 1,115 | 930 | 1,065 | 1,023 | 1,285 |
| Adjusted EBITDA | 224 | 243 | 192 | 148 | 177 | 177 |
| Adjusted EBITDA margin in % | 24.0 | 21.8 | 20.6 | 13.9 | 17.7 | 14.1 |
| Adjusted EBIT | 181 | 194 | 127 | 82 | 111 | 103 |
| Capital expendituresa | 20 | 28 | 30 | 64 | 78 | 69 |
| Financial investments | – | – | 49 | – | 1 | 1 |
a For intangible assets, property, plant and equipment.
| Europe, Middle East & Africa | North America | |||||
|---|---|---|---|---|---|---|
| in € million | 2021 | 2022 | 2021 | 2022 | ||
| External salesa | 1,891 | 2,520 | 911 | 1,193 | ||
| Capital expenditures | 139 | 149 | 23 | 53 |
a External sales Europe, Middle East & Africa: thereof Germany €715 million (Q3 2021: €638 million).
| Performance Materials Technology & Infrastructure |
Enabling functions, other activities, consolidation |
Total Group (continuing operations) |
|||||
|---|---|---|---|---|---|---|---|
| 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 |
| 784 | 903 | 204 | 525 | 16 | 16 | 3,871 | 4,878 |
| 40 | 54 | 365 | 443 | -427 | -528 | – | – |
| 824 | 957 | 569 | 968 | -411 | -512 | 3,871 | 4,878 |
| 97 | 74 | 27 | 35 | -72 | -62 | 645 | 615 |
| 12.4 | 8.2 | 13.2 | 6.7 | – | – | 16.7 | 12.6 |
| 63 | 39 | -1 | 6 | -94 | -82 | 387 | 342 |
| 14 | 16 | 34 | 31 | 6 | 13 | 182 | 221 |
| – | – | – | – | 3 | 10 | 53 | 11 |
| Central & South America | Asia-Pacific | Total Group (continuing operations) |
|||
|---|---|---|---|---|---|
| 2021 | 2022 | 2021 | 2022 | 2021 | 2022 |
| 186 | 260 | 883 | 905 | 3,871 | 4,878 |
| 4 | 2 | 16 | 17 | 182 | 221 |
| Specialty Additives | Nutrition & Care | Smart Materials | |||||
|---|---|---|---|---|---|---|---|
| in € million | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | |
| External sales | 2,763 | 3,278 | 2,549 | 3,127 | 2,885 | 3,677 | |
| Internal sales | 7 | 6 | 5 | 8 | 46 | 68 | |
| Total sales | 2,770 | 3,284 | 2,554 | 3,135 | 2,931 | 3,745 | |
| Adjusted EBITDA | 739 | 758 | 517 | 555 | 527 | 572 | |
| Adjusted EBITDA margin in % | 26.7 | 23.1 | 20.3 | 17.7 | 18.3 | 15.6 | |
| Adjusted EBIT | 609 | 613 | 327 | 357 | 329 | 355 | |
| Capital expendituresa | 50 | 68 | 85 | 130 | 224 | 174 | |
| Financial investments | – | – | 49 | 1 | 5 | 12 | |
| No. of employees as of September 30 | 3,704 | 3,785 | 5,386 | 5,680 | 7,731 | 7,919 |
a For intangible assets, property, plant and equipment.
| Europe, Middle East & Africa | North America | ||||
|---|---|---|---|---|---|
| in € million | 2021 | 2022 | 2021 | 2022 | |
| External salesa | 5,336 | 7,260 | 2,538 | 3,333 | |
| Non-current assets in accordance with IFRS 8 as of September 30 | 7,329 | 7,717 | 4,182 | 4,853 | |
| Capital expenditures | 406 | 361 | 61 | 114 | |
| No. of employees as of September 30 | 22,366 | 22,876 | 4,795 | 5,011 |
Prior-year figures restated.
a External sales Europe, Middle East & Africa: thereof Germany €2,214 million (9M 2021: €1,784 million).
| Performance Materials | Technology & Infrastructure | Enabling functions, other activities, consolidation |
Total Group (continuing operations) |
|||||
|---|---|---|---|---|---|---|---|---|
| 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | |
| 2,071 | 2,893 | 553 | 1,124 | 44 | 49 | 10,865 | 14,148 | |
| 96 | 166 | 1,064 | 1,297 | -1,218 | -1,545 | – | – | |
| 2,167 | 3,059 | 1,617 | 2,421 | -1,174 | -1,496 | 10,865 | 14,148 | |
| 237 | 334 | 82 | 65 | -221 | -207 | 1,881 | 2,077 | |
| 11.4 | 11.5 | 14.8 | 5.8 | – | – | 17.3 | 14.7 | |
| 138 | 234 | -1 | -21 | -281 | -268 | 1,121 | 1,270 | |
| 32 | 39 | 84 | 71 | 30 | 37 | 505 | 519 | |
| – | 1 | – | – | 7 | 18 | 61 | 32 | |
| 1,962 | 2,031 | 8,154 | 8,308 | 5,954 | 6,113 | 32,891 | 33,836 |
| Central & South America | Asia-Pacific | Total Group (continuing operations) |
|||
|---|---|---|---|---|---|
| 2021 | 2022 | 2021 | 2022 | 2021 | 2022 |
| 490 | 741 | 2,501 | 2,814 | 10,865 | 14,148 |
| 164 | 173 | 1,877 | 1,885 | 13,552 | 14,628 |
| 6 | 5 | 32 | 39 | 505 | 519 |
| 699 | 728 | 5,031 | 5,221 | 32,891 | 33,836 |
The presentation of the adjustments was altered as of December 31, 2021. Irrespective of their classification as adjustments, they are now allocated to the relevant function costs. The prior-year figures have been restated.
| 2021 | |||
|---|---|---|---|
| in € million | 3rd quarter | 1st nine months |
|
| Sales | – | – | |
| Cost of sales | -5 | -21 | |
| Gross profit on sales | -5 | -21 | |
| Selling expenses | – | -2 | |
| Research and development expenses | – | – | |
| General administrative expenses | -3 | -5 | |
| Other operating income | – | -3 | |
| Other operating expense | 8 | 31 | |
| Result from investments recognized at equity | – | – | |
| Income before financial result and income taxes, continuing operations (EBIT) | – | – |
The definition of non-current assets in accordance with IFRS 8 Operating Segments was adjusted as of December 31, 2021. Alongside goodwill, other intangible assets, property, plant and equipment, and right-of-use assets, non-current assets in accordance with IFRS 8 now also include investments recognized at equity and non-current other non-financial assets. The prior-year figures have been restated.
The TAA derivatives business of the Specialty Additives division is presented as held for sale on the balance sheet as of September 30, 2022. TAA derivatives are essential precursors for the production of light stabilizers. The business includes property, plant and equipment of €35 million and goodwill of €22 million.
| Event | Date |
|---|---|
| Report on Q4 2022 and FY 2022 | March 2, 2023 |
| Interim report Q1 2023 | May 9, 2023 |
| Annual shareholders' meeting 2023 | May 31, 2023 |
| Interim report Q2 2023 | August 4, 2023 |
| Interim report Q3 2023 | November 7, 2023 |
Evonik Industries AG Rellinghauser Strasse 1–11 45128 Essen, Germany www.evonik.com
Phone +49 201 177-3315 [email protected]
Phone +49 201 177-3146 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.